MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-18-2026
Charles River Laboratories International Interest Expense 2011-2026 | CRL
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Charles River Laboratories International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22.6 M | -16.5 M | 95.5 M | 30.5 M | 73.9 M | 86.4 M | 60.9 M | 63.8 M | 29.8 M | 27.7 M | 15.1 M | 12 M | 21 M | 33.3 M | 42.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 95.5 M | -22.6 M | 36.9 M |
Quarterly Interest Expense Charles River Laboratories International
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22.6 M | 154 K | -12.2 M | - | 2.59 M | -2.24 M | 5.83 M | - | -6.26 M | -2.66 M | 34.4 M | - | 11.4 M | 3.7 M | 9.43 M | - | 16.5 M | 16.2 M | 29.7 M | - | 18.9 M | 19.4 M | 15.1 M | - | 5.7 M | 20.8 M | 9.99 M | - | 17.2 M | 18.6 M | 11.2 M | - | 7.67 M | 7.4 M | 6.98 M | - | 7.08 M | 8.91 M | 4.21 M | - | 3.85 M | 4.38 M | 3.02 M | - | 3 M | 3.37 M | 2.8 M | - | 2.32 M | 7.54 M | 8.28 M | - | 8.52 M | 8.08 M | 8.44 M | - | 11.9 M | 10.7 M | 10 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 34.4 M | -22.6 M | 7.98 M |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
500 K | $ 2.86 | -3.38 % | $ 92.8 K |  USA |
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
81 M | $ 118.89 | 0.64 % | $ 36.1 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 13.75 | -3.17 % | $ 416 M | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 107.73 | -0.5 % | $ 8.89 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
29.8 M | $ 636.84 | 0.02 % | $ 51.2 B | USA |
 |
Illumina
ILMN
|
-292 M | $ 130.15 | -2.06 % | $ 20.7 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 108.05 | -0.24 % | $ 4.26 B | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
1 K | $ 27.48 | -1.84 % | $ 763 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 283.25 | -1.05 % | $ 23.6 B | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 79.36 | 4.01 % | $ 5.36 B | USA |
 |
Mettler-Toledo International
MTD
|
68.5 M | $ 1 318.91 | -0.31 % | $ 27.2 B |  Schweiz |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
Myriad Genetics
MYGN
|
800 K | $ 5.21 | 3.89 % | $ 482 M | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 9.59 | 0.89 % | $ 1.23 B | USA |
 |
Natera
NTRA
|
9.32 M | $ 208.22 | 4.02 % | $ 20.5 B | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Pacific Biosciences of California
PACB
|
14.8 M | $ 1.52 | -6.17 % | $ 456 M | USA |
 |
Precipio
PRPO
|
-1 K | $ 24.7 | 0.08 % | $ 32.1 M | USA |
|
Biodesix
BDSX
|
8.26 M | $ 15.67 | -0.51 % | $ 2.03 B | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Senseonics Holdings
SENS
|
-23 K | $ 6.82 | -17.66 % | $ 285 M | USA |
 |
Sotera Health Company
SHC
|
8.55 M | $ 15.74 | -1.06 % | $ 4.47 B | USA |
 |
Soleno Therapeutics
SLNO
|
110 K | $ 38.17 | -2.28 % | $ 1.94 B | USA |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.12 | -2.19 % | $ 1.42 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 208.58 | -0.79 % | $ 23.2 B | USA |
 |
Danaher Corporation
DHR
|
-222 M | $ 204.29 | -0.83 % | $ 146 B | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 103.36 | - | $ 19.5 B | USA |
 |
Bioventus
BVS
|
1.29 M | $ 8.78 | 0.11 % | $ 550 M | USA |
 |
DarioHealth Corp.
DRIO
|
-31 K | $ 10.3 | -4.19 % | $ 292 M |  Israel |
 |
DexCom
DXCM
|
177 M | $ 72.86 | -1.24 % | $ 28.4 B | USA |
 |
Thermo Fisher Scientific
TMO
|
-12 M | $ 507.94 | -0.1 % | $ 191 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-903 K | $ 47.14 | 2.72 % | $ 2.82 B | USA |
 |
QIAGEN N.V.
QGEN
|
-739 K | - | - | $ 10.6 B |  Niderland |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 24.01 | -6.38 % | $ 254 M | China |
 |
VolitionRx Limited
VNRX
|
-233 K | $ 0.2 | -2.22 % | $ 19.2 M |  Singapore |
 |
CareDx, Inc
CDNA
|
524 K | $ 18.74 | -0.03 % | $ 999 M | USA |
 |
Waters Corporation
WAT
|
14.3 M | $ 311.27 | 1.35 % | $ 18.5 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M | Israel |
 |
Guardant Health
GH
|
-10.5 M | $ 94.75 | 2.73 % | $ 11.9 B | USA |
 |
IQVIA Holdings
IQV
|
729 M | $ 173.82 | -0.27 % | $ 29.9 B | USA |